

# Tafamidis

**Catalog No: tcsc2821** 

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

© Specifications

CAS No:

594839-88-0

Formula:

 $\mathsf{C}_{14}\mathsf{H}_{7}\mathsf{Cl}_{2}\mathsf{NO}_{3}$ 

## Pathway:

Others

#### **Target:** Others

### Purity / Grade:

>98%

Solubility:

DMSO : ≥ 54 mg/mL (175.26 mM)

#### **Alternative Names:**

Fx-1006A

Copyright 2021 Taiclone Biotech Corp.



#### **Observed Molecular Weight:**


308.12

# **Product Description**

Tafamidis(Fx1006A) is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Target: Others

Tafamidis is a drug for the amelioration of transthyretin-related hereditary amyloidosis. Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein. Tafamidis binds selectively and with negative cooperativity (K(d)s  $\sim$ 2 nM and  $\sim$ 200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer, and kinetically stabilizes TTR. Patient-derived amyloidogenic variants of TTR, including kinetically and thermodynamically less stable mutants, are also stabilized by tafamidis binding. The crystal structure of tafamidis-bound TTR suggests that binding stabilizes the weaker dimer-dimer interface against dissociation, the rate-limiting step of amyloidogenesis [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.